

# Elias J Jabbour

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9319541/publications.pdf>

Version: 2024-02-01

341  
papers

22,445  
citations

6613

79  
h-index

12946

131  
g-index

345  
all docs

345  
docs citations

345  
times ranked

15235  
citing authors

#	ARTICLE	IF	CITATIONS
1	Intrathecal prophylaxis with 12 versus 8 administrations reduces the incidence of central nervous system relapse in patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia. American Journal of Hematology, 2023, 98, .	4.1	11
2	SOHO State of the Art Updates & Next Questions: Intensive and Non-Intensive Approaches for Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 61-66.	0.4	5
3	The cure of leukemia through the optimist's prism. Cancer, 2022, 128, 240-259.	4.1	17
4	Prediction of early (4-week) mortality in acute myeloid leukemia with intensive chemotherapy. American Journal of Hematology, 2022, 97, 68-78.	4.1	25
5	Venetoclax and hypomethylating agents in older/unfit patients with blastic plasmacytoid dendritic cell neoplasm. American Journal of Hematology, 2022, 97, E62.	4.1	17
6	Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure. Journal of Hematology and Oncology, 2022, 15, 12.	17.0	13
7	Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD. Blood Advances, 2022, 6, 3027-3035.	5.2	17
8	Improved outcomes among newly diagnosed patients with <scp>FMS&#x2191;like tyrosine kinase 3 internal tandem duplication</scp> mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification. American Journal of Hematology, 2022, 97, 329-337.	4.1	15
9	Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib. Leukemia, 2022, 36, 1253-1260.	7.2	9
10	Dismal outcomes of patients with relapsed/refractory Philadelphia chromosome&#x2013;negative B&#x2013;cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab. American Journal of Hematology, 2022, 97, .	4.1	7
11	Clinical Value of Measurable Residual Disease in Acute Lymphoblastic Leukemia. Blood and Lymphatic Cancer: Targets and Therapy, 2022, Volume 12, 7-16.	2.7	9
12	<scp>Treatment&#x2013;free</scp> remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors. American Journal of Hematology, 2022, 97, 856-864.	4.1	33
13	Prediction of survival with intensive chemotherapy in acute myeloid leukemia. American Journal of Hematology, 2022, 97, 865-876.	4.1	12
14	<i>TP53</i> copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia. Blood, 2022, 140, 58-72.	1.4	46
15	Prediction for sustained deep molecular response for treatment-free remission. Leukemia and Lymphoma, 2022, 63, 5-6.	1.3	0
16	Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trials. American Journal of Hematology, 2022, 97, 885-894.	4.1	4
17	A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia. Leukemia and Lymphoma, 2022, 63, 2161-2170.	1.3	12
18	Ponatinib for the treatment of adult patients with resistant or intolerant Chronic-Phase Chronic Myeloid Leukemia. Expert Opinion on Pharmacotherapy, 2022, 23, 751-758.	1.8	3

#	ARTICLE	IF	CITATIONS
19	Time to First Subsequent Salvage Therapy in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia Treated With Inotuzumab Ozogamicin in the Phase III INO-VATE Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e836-e843.	0.4	1
20	Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study. <i>Lancet Haematology</i> , 2022, 9, e350-e360.	4.6	26
21	Hypomethylating agent and venetoclax with FLT3 inhibitor $\alpha$ -triptet therapy in older/unfit patients with FLT3 mutated AML. <i>Blood Cancer Journal</i> , 2022, 12, 77.	6.2	33
22	High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse. <i>Blood Advances</i> , 2022, 6, 4006-4014.	5.2	37
23	Venetoclax combined with FLAG induction and consolidation in newly diagnosed acute myeloid leukemia. <i>American Journal of Hematology</i> , 2022, 97, 1035-1043.	4.1	31
24	Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring. <i>American Journal of Hematology</i> , 2022, 97, 1236-1256.	4.1	68
25	Blinatumomab is associated with favorable outcomes in patients with B-cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of $10^{-4}$ and higher. <i>American Journal of Hematology</i> , 2022, 97, 1135-1141.	4.1	6
26	Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacididine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2022, 40, 3848-3857.	1.6	41
27	Treatment of Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia From Intensive Chemotherapy Combinations to Chemotherapy-Free Regimens. <i>JAMA Oncology</i> , 2022, 8, 1340.	7.1	30
28	Real-life incidence of thrombotic events in leukemia patients treated with ponatinib. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	4
29	Treating Leukemia in the Time of COVID-19. <i>Acta Haematologica</i> , 2021, 144, 132-145.	1.4	57
30	Clinical outcomes and influence of mutation clonal dominance in oligomonocytic and classical chronic myelomonocytic leukemia. <i>American Journal of Hematology</i> , 2021, 96, E50-E53.	4.1	8
31	The Hyper-CVAD Regimen is an Optimal Pediatric-inspired Regimen for Adolescents and Adults With Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 63-65.	0.4	3
32	Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality. <i>American Journal of Hematology</i> , 2021, 96, 282-291.	4.1	59
33	<i>GATA3</i> rs3824662A allele in B-cell acute lymphoblastic leukemia in adults, adolescents and young adults: association with <i>CRLF2</i> rearrangement and poor prognosis. <i>American Journal of Hematology</i> , 2021, 96, E71-E74.	4.1	5
34	Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 Inhibitors. <i>Blood Cancer Discovery</i> , 2021, 2, 125-134.	5.0	50
35	The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase: A model to improve patient outcomes. <i>American Journal of Hematology</i> , 2021, 96, 241-250.	4.1	19
36	Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia. <i>Cancer</i> , 2021, 127, 905-913.	4.1	30

#	ARTICLE	IF	CITATIONS
37	Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3 $\Delta$ ITD and IDH mutations. <i>Cancer</i> , 2021, 127, 381-390.	4.1	10
38	Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission. <i>Cancer</i> , 2021, 127, 1894-1900.	4.1	5
39	CML Therapy: A Focus on Second- and Third-Generation Tyrosine Kinase Inhibitors. <i>Hematologic Malignancies</i> , 2021, , 61-76.	0.2	0
40	Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. <i>Cancer Discovery</i> , 2021, 11, 1440-1453.	9.4	137
41	Acute myeloid leukemia: current progress and future directions. <i>Blood Cancer Journal</i> , 2021, 11, 41.	6.2	313
42	Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22. <i>Clinical Cancer Research</i> , 2021, 27, 2742-2754.	7.0	16
43	The clinical development of antibody-“drug conjugates” lessons from leukaemia. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 418-433.	27.6	28
44	Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis. <i>Blood Cancer Journal</i> , 2021, 11, 52.	6.2	5
45	Outcome of T-cell acute lymphoblastic leukemia/lymphoma: Focus on near-ETP phenotype and differential impact of nelarabine. <i>American Journal of Hematology</i> , 2021, 96, 589-598.	4.1	42
46	Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-“hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-“negative acute lymphoblastic leukemia. <i>Cancer</i> , 2021, 127, 2025-2038.	4.1	24
47	A new era in the treatment of acute lymphoblastic leukemia. <i>Blood</i> , 2021, 137, 1563-1564.	1.4	3
48	Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis ( $\langle$ sc $\rangle$ MDS/MPN $\langle$ RS $\rangle$ ) and myelodysplastic syndrome with ring sideroblasts ( $\langle$ sc $\rangle$ MDS $\langle$ RS $\rangle$ ). <i>American Journal of Hematology</i> , 2021, 96, E246-E249.	4.1	9
49	A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. <i>Haematologica</i> , 2021, 106, 2121-2130.	3.5	34
50	Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia. <i>Cancer</i> , 2021, 127, 3113-3124.	4.1	5
51	Acute lymphoblastic leukemia: A population-based study of outcome in the $\langle$ sc $\rangle$ United $\langle$ sc $\rangle$ States based on the surveillance, epidemiology, and end results ( $\langle$ sc $\rangle$ SEER $\langle$ sc $\rangle$ ) database, $\langle$ sc $\rangle$ 1980 $\langle$ sc $\rangle$ – $\langle$ sc $\rangle$ 2017 $\langle$ sc $\rangle$ . <i>American Journal of Hematology</i> , 2021, 96, 650-658.	4.1	52
52	Prognostic factors for progression in patients with Philadelphia chromosome-“positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors. <i>Cancer</i> , 2021, 127, 2648-2656.	4.1	33
53	Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-“positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinib. <i>Cancer</i> , 2021, 127, 2641-2647.	4.1	15
54	An effective chemotherapy-“free regimen of ponatinib plus venetoclax for relapsed/refractory $\langle$ sc $\rangle$ Philadelphia chromosome-“positive acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2021, 96, E229-E232.	4.1	17

#	ARTICLE	IF	CITATIONS
55	Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. <i>Blood Advances</i> , 2021, 5, 1876-1883.	5.2	56
56	Activity of venetoclax-based therapy in chronic myelomonocytic leukemia. <i>Leukemia</i> , 2021, 35, 1494-1499.	7.2	16
57	De novo acute myeloid leukemia: A population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017. <i>Cancer</i> , 2021, 127, 2049-2061.	4.1	79
58	<sc>FLT3</sc> inhibitor based induction and allogeneic stem cell transplant in complete remission 1 improve outcomes in patients with newly diagnosed <sc>Acute Myeloid Leukemia</sc> with very low <sc>FLT3</sc> allelic burden. <i>American Journal of Hematology</i> , 2021, 96, E275-E279.	4.1	3
59	Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2021, 96, 1000-1007.	4.1	23
60	Clinical Outcomes of Patients With Chronic Myeloid Leukemia With Concurrent Core Binding Factor Rearrangement and Philadelphia Chromosome. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 338-344.	0.4	7
61	Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. <i>Leukemia</i> , 2021, 35, 3421-3429.	7.2	22
62	Long-term results of low-intensity chemotherapy with clofarabine or cladribine combined with low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. <i>American Journal of Hematology</i> , 2021, 96, 914-924.	4.1	13
63	Combination of ponatinib and blinatumomab in Philadelphia chromosome-positive acute lymphoblastic leukemia: Early results from a phase II study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 7001-7001.	1.6	18
64	Immunotherapy in Acute Myeloid Leukemia: Where We Stand. <i>Frontiers in Oncology</i> , 2021, 11, 656218.	2.8	63
65	Current Approaches to Philadelphia Chromosome-Positive B-Cell Lineage Acute Lymphoblastic Leukemia: Role of Tyrosine Kinase Inhibitor and Stem Cell Transplant. <i>Current Oncology Reports</i> , 2021, 23, 95.	4.0	4
66	Central nervous system involvement in blastic plasmacytoid dendritic cell neoplasm. <i>Blood</i> , 2021, 138, 1373-1377.	1.4	31
67	A phase 1b/2 study of azacitidine with PD-1 antibody avelumab in relapsed/refractory acute myeloid leukemia. <i>Cancer</i> , 2021, 127, 3761-3771.	4.1	34
68	Impact of frontline treatment approach on outcomes of myeloid blast phase CML. <i>Journal of Hematology and Oncology</i> , 2021, 14, 94.	17.0	19
69	Therapeutic implications of menin inhibition in acute leukemias. <i>Leukemia</i> , 2021, 35, 2482-2495.	7.2	76
70	Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. <i>Cancer</i> , 2021, 127, 3381-3389.	4.1	10
71	Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms. <i>Leukemia</i> , 2021, 35, 3044-3058.	7.2	29
72	Only <i>SF3B1</i> mutation involving K700E independently predicts overall survival in myelodysplastic syndromes. <i>Cancer</i> , 2021, 127, 3552-3565.	4.1	19

#	ARTICLE	IF	CITATIONS
73	Impact of Philadelphia chromosome-like alterations on efficacy and safety of blinatumomab in adults with relapsed/refractory acute lymphoblastic leukemia: A post hoc analysis from the phase 3 TOWER study. American Journal of Hematology, 2021, 96, E379-E383.	4.1	12
74	Long term outcome of Hyper-CVAD-R for Burkitt leukemia/lymphoma and high-grade B-cell lymphoma: focus on CNS relapse. Blood Advances, 2021, 5, 3913-3918.	5.2	5
75	Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia. JAMA Oncology, 2021, 7, 1213.	7.1	53
76	Development of TP53 mutations over the course of therapy for acute myeloid leukemia. American Journal of Hematology, 2021, 96, 1420-1428.	4.1	10
77	A phase 2a, single-arm, open-label study of tafasitamab, a humanized, Fc-modified, anti-CD19 antibody, in patients with relapsed/refractory B-precursor cell acute lymphoblastic leukemia. Cancer, 2021, 127, 4190-4197.	4.1	6
78	Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score-matched analysis. Cancer, 2021, 127, 4213-4220.	4.1	24
79	Hyper-CVAD in 2021: Lessons Learned and New Approaches. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S82-S84.	0.4	0
80	Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements. Blood Cancer Journal, 2021, 11, 162.	6.2	32
81	Outcomes of acute lymphoblastic leukemia with KMT2A (<i>MLL</i>) rearrangement: the MD Anderson experience. Blood Advances, 2021, 5, 5415-5419.	5.2	24
82	Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. Journal of Clinical Oncology, 2021, 39, 2768-2778.	1.6	173
83	Frontline Therapy of Newly Diagnosed Acute Lymphoblastic Leukemia. Hematologic Malignancies, 2021, , 169-184.	0.2	0
84	Minimal or Measurable Residual Disease in Acute Lymphoblastic Leukemia. Hematologic Malignancies, 2021, , 205-218.	0.2	0
85	The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival. American Journal of Hematology, 2020, 95, 144-150.	4.1	25
86	Long-term follow-up of lower dose dasatinib (50mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia. Cancer, 2020, 126, 67-75.	4.1	87
87	Targeted therapy paves the way for the cure of acute lymphoblastic leukaemia. British Journal of Haematology, 2020, 188, 207-223.	2.5	20
88	FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions. Leukemia, 2020, 34, 682-696.	7.2	140
89	Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 212-218.	0.4	71
90	Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia. Cancer, 2020, 126, 765-774.	4.1	69

#	ARTICLE	IF	CITATIONS
91	The face of remission induction. <i>British Journal of Haematology</i> , 2020, 188, 101-115.	2.5	3
92	Optimizing the use of the hyperCVAD regimen: Clinical vignettes and practical management. <i>Cancer</i> , 2020, 126, 1152-1160.	4.1	29
93	Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial. <i>Leukemia Research</i> , 2020, 88, 106283.	0.8	32
94	10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. <i>Lancet Haematology</i> , 2020, 7, e724-e736.	4.6	201
95	Nelarabine-related rhabdomyolysis in a patient with T-cell acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 2775-2777.	1.3	4
96	Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2020, 95, 1288-1295.	4.1	28
97	Monoclonal antibodies in frontline acute lymphoblastic leukemia. <i>Best Practice and Research in Clinical Haematology</i> , 2020, 33, 101226.	1.7	3
98	Antibody based therapy in relapsed acute lymphoblastic leukemia. <i>Best Practice and Research in Clinical Haematology</i> , 2020, 33, 101225.	1.7	6
99	Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden. <i>Blood Cancer Journal</i> , 2020, 10, 81.	6.2	34
100	Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. <i>Lancet Haematology</i> , 2020, 7, e523-e533.	4.6	43
101	Outcome of patients with IDH1/2-mutated post-transformation myeloproliferative neoplasm AML in the era of IDH inhibitors. <i>Blood Advances</i> , 2020, 4, 5336-5342.	5.2	37
102	Natural history of newly diagnosed myelodysplastic syndrome with isolated inv(3)/t(3;3). <i>American Journal of Hematology</i> , 2020, 95, E326-E329.	4.1	2
103	Management of Older Patients with Acute Lymphocytic Leukemia – Novel Treatment Strategies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S30-S31.	0.4	1
104	Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies. <i>Annals of Hematology</i> , 2020, 99, 2215-2229.	1.8	29
105	Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin. <i>British Journal of Haematology</i> , 2020, 191, e77-e81.	2.5	3
106	Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies. <i>Lancet</i> , 2020, 396, 1885-1894.	13.7	206
107	Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML. <i>Blood Advances</i> , 2020, 4, 6117-6126.	5.2	29
108	Recent Advances in Managing Acute Lymphoblastic Leukemia. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 330-342.	3.8	40

#	ARTICLE	IF	CITATIONS
109	Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed/refractory acute lymphoblastic leukemia: an update from the INO-VATE final study database. <i>Leukemia and Lymphoma</i> , 2020, 61, 2012-2015.	1.3	10
110	Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL. <i>Blood Cancer Journal</i> , 2020, 10, 61.	6.2	20
111	Salvage Therapy Outcomes in a Historical Cohort of Patients With Relapsed or Refractory Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e871-e882.	0.4	10
112	Outcome of adults with relapsed/refractory Tâ€cell acute lymphoblastic leukemia or lymphoblastic lymphoma. <i>American Journal of Hematology</i> , 2020, 95, E245-E247.	4.1	16
113	Gilteritinib in the treatment of relapsed and refractory acute myeloid leukemia with a FLT3 mutation. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072093061.	2.5	10
114	The clinical impact of time to response in de novo acceleratedâ€phase chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2020, 95, 1127-1134.	4.1	8
115	Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions. <i>Journal of Hematology and Oncology</i> , 2020, 13, 70.	17.0	100
116	Evaluation and management of measurable residual disease in acute lymphoblastic leukemia. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072091002.	2.5	25
117	Phase 2 study of hyperâ€CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2020, 95, 734-739.	4.1	10
118	A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia. <i>Leukemia</i> , 2020, 34, 2489-2492.	7.2	37
119	Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy. <i>American Journal of Hematology</i> , 2020, 95, 612-622.	4.1	51
120	Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors. <i>Cancer</i> , 2020, 126, 2193-2205.	4.1	33
121	Longâ€term results of frontline dasatinib in chronic myeloid leukemia. <i>Cancer</i> , 2020, 126, 1502-1511.	4.1	21
122	Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. <i>American Journal of Hematology</i> , 2020, 95, 691-709.	4.1	229
123	Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias. <i>Acta Haematologica</i> , 2020, 143, 567-573.	1.4	53
124	Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes. <i>Blood Advances</i> , 2020, 4, 482-495.	5.2	86
125	Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens. <i>Blood Advances</i> , 2020, 4, 1311-1320.	5.2	106
126	Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with <i>FLT3</i>-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Haematologica</i> , 2020, 105, 1507-1516.	3.5	91



#	ARTICLE	IF	CITATIONS
127	Long-term results of a phase 2 trial of nilotinib 400Âmg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia. <i>Cancer</i> , 2020, 126, 1448-1459.	4.1	14
128	Interim Results of the Phase I/II Study of the Ponatinib, Venetoclax and Dexamethasone for Patients with Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Blood</i> , 2020, 136, 11-12.	1.4	4
129	Hyper-CVAD and Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia: Results from a Phase II Study. <i>Blood</i> , 2020, 136, 9-11.	1.4	13
130	Reduced-Intensity Chemotherapy with Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study. <i>Blood</i> , 2020, 136, 15-17.	1.4	14
131	Outcome of Patients with T-Cell Acute Lymphoblastic Leukemia/Lymphoma with Early T-Cell Precursor-like Immunophenotype with Strong CD5 Expression. <i>Blood</i> , 2020, 136, 38-40.	1.4	1
132	Ultrasensitive Next-Generation Sequencing-Based Measurable Residual Disease Assessment in Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia after Frontline Therapy: Correlation with Flow Cytometry and Impact on Clinical Outcomes. <i>Blood</i> , 2020, 136, 26-28.	1.4	5
133	Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL): Focus on MRD Results. <i>Blood</i> , 2020, 136, 42-43.	1.4	11
134	Inotuzumab ozogamicin (INO) plus bosutinib (BOS) in R/R PH+ ALL or CML in lymphoid blast phase (CML) Tj ETQq0,0,0 rgBT /Overlock 1	1.6	7
135	Venetoclax (Ven) added to intensive chemo with cladribine, idarubicin, and AraC (CLIA) achieves high rates of durable complete remission with low rates of measurable residual disease (MRD) in pts with newly diagnosed acute myeloid leukemia (AML).. <i>Journal of Clinical Oncology</i> , 2020, 38, 7539-7539.	1.6	6
136	Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study. <i>Cancer</i> , 2019, 125, 4181-4192.	4.1	61
137	Maintenance therapy in AML: The past, the present and the future. <i>American Journal of Hematology</i> , 2019, 94, 1254-1265.	4.1	56
138	Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3â€internal tandem duplication mutationâ€positive acute myeloid leukemia. <i>Cancer</i> , 2019, 125, 3755-3766.	4.1	38
139	SOHO State of the Art Update and Next Questions: Advances in the Treatment of Adult Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 471-479.	0.4	2
140	Reply to Miniâ€HCVD plus inotuzumab plus or minus blinatumomab: Hype or hope?. <i>Cancer</i> , 2019, 125, 3891-3892.	4.1	0
141	Philadelphia chromosomeâ€positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors. <i>American Journal of Hematology</i> , 2019, 94, 1388-1395.	4.1	26
142	Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States. <i>Cancer Medicine</i> , 2019, 8, 6559-6565.	2.8	24
143	Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study. <i>Lancet Haematology</i> , the, 2019, 6, e480-e488.	4.6	103
144	Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantation. <i>American Journal of Hematology</i> , 2019, 94, 1382-1387.	4.1	20

#	ARTICLE	IF	CITATIONS
145	Sudden blastic transformation in treatment-free remission chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2019, 187, 543-545.	2.5	24
146	Phase 1/2 study of DFP-10917 administered by continuous intravenous infusion in patients with recurrent or refractory acute myeloid leukemia. <i>Cancer</i> , 2019, 125, 1665-1673.	4.1	5
147	Novel monoclonal antibody-based treatment strategies in adults with acute lymphoblastic leukemia. <i>Therapeutic Advances in Hematology</i> , 2019, 10, 204062071984949.	2.5	18
148	Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia. <i>Cancer</i> , 2019, 125, 3219-3224.	4.1	14
149	Ibrutinib and Venetoclax for First-Line Treatment of CLL. <i>New England Journal of Medicine</i> , 2019, 380, 2095-2103.	27.0	388
150	Early T precursor acute lymphoblastic leukaemia/lymphoma shows differential immunophenotypic characteristics including frequent CD33 expression and <i>in vitro</i> response to targeted CD33 therapy. <i>British Journal of Haematology</i> , 2019, 186, 538-548.	2.5	21
151	Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial. <i>Lancet Haematology</i> , 2019, 6, e317-e327.	4.6	71
152	Recent advances in the treatment of acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2019, 60, 2606-2621.	1.3	65
153	Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. <i>Cancer</i> , 2019, 125, 2579-2586.	4.1	63
154	Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors. <i>International Journal of Hematology</i> , 2019, 109, 545-552.	1.6	25
155	NPM1 mutant variant allele frequency correlates with leukemia burden but does not provide prognostic information in NPM1-mutated acute myeloid leukemia. <i>American Journal of Hematology</i> , 2019, 94, E158-E160.	4.1	17
156	Relapsed acute lymphoblastic leukemia with aberrant myeloperoxidase expression following CAR T-cell therapy: A diagnostic challenge. <i>American Journal of Hematology</i> , 2019, 94, 1049-1051.	4.1	11
157	Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. <i>Cancer</i> , 2019, 125, 2474-2487.	4.1	210
158	Clonal hematopoiesis of indeterminate potential-associated mutations and risk of comorbidities in patients with myelodysplastic syndrome. <i>Cancer</i> , 2019, 125, 2233-2241.	4.1	19
159	Recent Advances in Adult Acute Lymphoblastic Leukemia. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 106-118.	2.3	21
160	Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs. <i>Blood Advances</i> , 2019, 3, 851-861.	5.2	88
161	NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy. <i>Blood Advances</i> , 2019, 3, 922-933.	5.2	84
162	Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. <i>Lancet Haematology</i> , 2019, 6, e29-e37.	4.6	84

#	ARTICLE	IF	CITATIONS
163	Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. <i>Cancer Discovery</i> , 2019, 9, 370-383.	9.4	380
164	Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience. <i>Journal of Hematology and Oncology</i> , 2019, 12, 1.	17.0	257
165	Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin. <i>American Journal of Hematology</i> , 2019, 94, 408-416.	4.1	11
166	CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia. <i>Haematologica</i> , 2019, 104, 749-755.	3.5	50
167	Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts. <i>American Journal of Hematology</i> , 2019, 94, 257-265.	4.1	99
168	A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents. <i>American Journal of Hematology</i> , 2019, 94, 74-79.	4.1	10
169	Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with <i>NPM1</i> and <i>FLT3</i> internal tandem duplication genotypes. <i>Cancer</i> , 2019, 125, 1091-1100.	4.1	50
170	The distribution of T cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. <i>Cancer</i> , 2019, 125, 1470-1481.	4.1	229
171	Efficacy and Safety Outcomes in the Phase 3 INO-Vate Trial By Baseline CD22 Positivity Assessed By Local Laboratories. <i>Blood</i> , 2019, 134, 1344-1344.	1.4	3
172	Venetoclax Combined with Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacitidine Produces High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML). <i>Blood</i> , 2019, 134, 2647-2647.	1.4	11
173	Long-Term Safety and Efficacy of Hyper-CVAD Plus Ponatinib As Frontline Therapy for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Blood</i> , 2019, 134, 283-283.	1.4	34
174	Fludarabine, Cytarabine, G-CSF and Gemtuzumab Ozogamicin (FLAG-GO) Regimen Results in Better Molecular Response and Relapse-Free Survival in Core Binding Factor Acute Myeloid Leukemia Than FLAG and Idarubicin (FLAG-Ida). <i>Blood</i> , 2019, 134, 290-290.	1.4	19
175	Safety and Efficacy of Venetoclax in Combination with Navitoclax in Adult and Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. <i>Blood</i> , 2019, 134, 285-285.	1.4	24
176	Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II Trial. <i>Blood</i> , 2019, 134, 2637-2637.	1.4	15
177	A Multicenter Phase I Study Combining Venetoclax with Mini-Hyper-CVD in Older Adults with Untreated and Relapsed/Refractory Acute Lymphoblastic Leukemia. <i>Blood</i> , 2019, 134, 3867-3867.	1.4	30
178	Characteristics and Clinical Outcomes of Patients with Acute Lymphoblastic Leukemia with KMT2A (MLL) Rearrangement. <i>Blood</i> , 2019, 134, 2582-2582.	1.4	2
179	Activity of venetoclax-based therapy in TP53-mutated acute myeloid leukemia.. <i>Journal of Clinical Oncology</i> , 2019, 37, 7034-7034.	1.6	8
180	Treatment-free remission in chronic myeloid leukemia. <i>Clinical Advances in Hematology and Oncology</i> , 2019, 17, 686-696.	0.3	6

#	ARTICLE	IF	CITATIONS
181	Patient-reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed/refractory acute lymphoblastic leukemia. <i>Cancer</i> , 2018, 124, 2151-2160.	4.1	44
182	Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000. <i>Cancer</i> , 2018, 124, 2534-2540.	4.1	23
183	Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. <i>Cancer</i> , 2018, 124, 2758-2765.	4.1	78
184	Efficacy of Ponatinib Versus Earlier Generation Tyrosine Kinase Inhibitors for Front-line Treatment of Newly Diagnosed Philadelphia-positive Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 257-265.	0.4	39
185	Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring. <i>American Journal of Hematology</i> , 2018, 93, 442-459.	4.1	291
186	Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE. <i>Cancer</i> , 2018, 124, 1722-1732.	4.1	43
187	Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2018, 19, 240-248.	10.7	192
188	Novel Therapies for Older Adults With Acute Lymphoblastic Leukemia. <i>Current Hematologic Malignancy Reports</i> , 2018, 13, 91-99.	2.3	15
189	Therapeutic choices after hypomethylating agent resistance for myelodysplastic syndromes. <i>Current Opinion in Hematology</i> , 2018, 25, 146-153.	2.5	22
190	Prediction for sustained deep molecular response of <i>BCR-ABL1</i> levels in patients with chronic myeloid leukemia in chronic phase. <i>Cancer</i> , 2018, 124, 1160-1168.	4.1	23
191	Early results of lower dose dasatinib (50%mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia. <i>Cancer</i> , 2018, 124, 2740-2747.	4.1	61
192	L-carnitine and Vitamin B Complex for the Treatment of Pegasparginase-induced Hyperbilirubinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e191-e195.	0.4	12
193	Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma. <i>American Journal of Hematology</i> , 2018, 93, 91-99.	4.1	74
194	Current paradigms in the management of Philadelphia chromosome positive acute lymphoblastic leukemia in adults. <i>American Journal of Hematology</i> , 2018, 93, 286-295.	4.1	38
195	Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors. <i>American Journal of Hematology</i> , 2018, 93, 84-90.	4.1	40
196	Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia. <i>JAMA Oncology</i> , 2018, 4, 230.	7.1	124
197	Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression. <i>American Journal of Hematology</i> , 2018, 93, 371-374.	4.1	68
198	Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia. <i>Cancer</i> , 2018, 124, 325-334.	4.1	57

#	ARTICLE	IF	CITATIONS
199	Clinical experience with the BCL-2 inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. <i>American Journal of Hematology</i> , 2018, 93, 401-407.	4.1	336
200	A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms. <i>American Journal of Hematology</i> , 2018, 93, 277-285.	4.1	54
201	Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2018, 36, 1788-1797.	1.6	156
202	Inotuzumab ozogamicin for the treatment of acute lymphoblastic leukemia. <i>Therapeutic Advances in Hematology</i> , 2018, 9, 347-356.	2.5	0
203	Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. <i>Lancet Haematology</i> , 2018, 5, e618-e627.	4.6	190
204	Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage. <i>Cancer</i> , 2018, 124, 4044-4055.	4.1	88
205	Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2018, 8, 369.	2.8	25
206	A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. <i>Blood</i> , 2018, 132, 1664-1674.	1.4	62
207	Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories. <i>Blood Advances</i> , 2018, 2, 1807-1816.	5.2	34
208	SOHO State of the Art Update and Next Questions: Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 439-446.	0.4	20
209	Prognosis of patients with intermediate risk IPSS myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS. <i>American Journal of Hematology</i> , 2018, 93, 1245-1253.	4.1	34
210	Sorafenib Combined with Azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia. <i>American Journal of Hematology</i> , 2018, 93, 1136-1141.	4.1	95
211	P53 protein overexpression in de novo acute myeloid leukemia patients with normal diploid karyotype correlates with FLT3 internal tandem duplication and worse relapse-free survival. <i>American Journal of Hematology</i> , 2018, 93, 1376-1383.	4.1	17
212	Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial. <i>Lancet Haematology</i> , 2018, 5, e411-e421.	4.6	66
213	Progress and Innovations in the Management of Adult Acute Lymphoblastic Leukemia. <i>JAMA Oncology</i> , 2018, 4, 1413.	7.1	69
214	Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD, with or without Blinatumomab, for Newly Diagnosed Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study. <i>Blood</i> , 2018, 132, 36-36.	1.4	12
215	Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) Vs. Standard Intensive Chemotherapy (hyper-CVAD) As Frontline Therapy for Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL): A Propensity Score Analysis. <i>Blood</i> , 2018, 132, 34-34.	1.4	4
216	Impact of minimal residual disease (MRD) status in clinical outcomes of patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) treated with inotuzumab ozogamicin (InO) in the phase 3 INO-VATE trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 7013-7013.	1.6	5

#	ARTICLE	IF	CITATIONS
217	Nivolumab (Nivo) maintenance (maint) in high-risk (HR) acute myeloid leukemia (AML) patients.. Journal of Clinical Oncology, 2018, 36, 7014-7014.	1.6	36
218	Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. Oncotarget, 2018, 9, 9714-9727.	1.8	56
219	Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents. American Journal of Hematology, 2017, 92, 351-358.	4.1	13
220	Minimal Residual Disease in Acute Lymphoblastic Leukemia: How to Recognize and Treat It. Current Oncology Reports, 2017, 19, 6.	4.0	32
221	Myeloid neoplasms with concurrent <i>BCR-ABL1</i> and <i>CBFB</i> rearrangements: A series of 10 cases of a clinically aggressive neoplasm. American Journal of Hematology, 2017, 92, 520-528.	4.1	23
222	Validation of the 2016 revisions to the WHO classification in lower-risk myelodysplastic syndrome. American Journal of Hematology, 2017, 92, E168-E171.	4.1	5
223	Factors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemia. American Journal of Hematology, 2017, 92, 924-928.	4.1	17
224	<i>TP53</i> mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens. Cancer, 2017, 123, 3717-3724.	4.1	18
225	A phase 1 study of AMG 900, an orally administered pan-aurora kinase inhibitor, in adult patients with acute myeloid leukemia. American Journal of Hematology, 2017, 92, 660-667.	4.1	26
226	Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents. American Journal of Hematology, 2017, 92, 599-606.	4.1	38
227	Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma. American Journal of Hematology, 2017, 92, E114-E117.	4.1	32
228	Acute lymphoblastic leukemia in adolescents and young adults. Cancer, 2017, 123, 2398-2403.	4.1	49
229	Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults. Blood, 2017, 129, 572-581.	1.4	285
230	Poor outcomes associated with +der(22)t(9;22) and $\sim 9/9p$ in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor. American Journal of Hematology, 2017, 92, 238-243.	4.1	41
231	Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood, 2017, 129, 1275-1283.	1.4	214
232	Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission. American Journal of Hematology, 2017, 92, 279-285.	4.1	32
233	Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation. American Journal of Hematology, 2017, 92, 331-337.	4.1	39
234	Reply to ABCG2 overexpression and deoxyadenosine analogue activity in acute myeloid leukemia. Cancer, 2017, 123, 4935-4936.	4.1	1

#	ARTICLE	IF	CITATIONS
235	Clinical outcomes in adult patients with aplastic anemia: A single institution experience. American Journal of Hematology, 2017, 92, 1295-1302.	4.1	13
236	Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 897-901.	0.4	127
237	Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study. Lancet Haematology, the, 2017, 4, e387-e398.	4.6	158
238	A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia. Cancer, 2017, 123, 4430-4439.	4.1	37
239	Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients. Cancer, 2017, 123, 4391-4402.	4.1	114
240	Clinical characteristics and outcomes of previously untreated patients with adult onset Tâ€acute lymphoblastic leukemia and Tâ€lymphoblastic lymphoma with hyperâ€CVAD based regimens. American Journal of Hematology, 2017, 92, E595-E597.	4.1	8
241	Which tyrosine kinase inhibitor should we use to treat Philadelphia chromosome-positive acute lymphoblastic leukemia?. Best Practice and Research in Clinical Haematology, 2017, 30, 193-200.	1.7	27
242	Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory <sc>B</sc>â€cell acute lymphoblastic leukemia. Cancer, 2017, 123, 294-302.	4.1	70
243	Phase 2 study of lowâ€dose clofarabine plus cytarabine for patients with higherâ€risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents. Cancer, 2017, 123, 629-637.	4.1	31
244	Prognostic impact of pretreatment cytogenetics in adult <sc>P</sc>hiladelphia chromosomeâ€negative acute lymphoblastic leukemia in the era of minimal residual disease. Cancer, 2017, 123, 459-467.	4.1	49
245	Dorsal column myelopathy after intrathecal chemotherapy for leukemia. American Journal of Hematology, 2017, 92, 155-160.	4.1	30
246	Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia. Cancer, 2017, 123, 426-435.	4.1	63
247	Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis. Blood Advances, 2017, 1, 1312-1323.	5.2	83
248	Phase 2 Study of Combination of Cytarabine, Idarubicin, and Nivolumab for Initial Therapy of Patients with Newly Diagnosed Acute Myeloid Leukemia. Blood, 2017, 130, 815-815.	1.4	11
249	Frontline hyper-CVAD plus ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Updated results of a phase II study.. Journal of Clinical Oncology, 2017, 35, 7013-7013.	1.6	18
250	Impact of dose reductions on 5-year efficacy in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML-CP) from DASISION.. Journal of Clinical Oncology, 2017, 35, 7051-7051.	1.6	18
251	Treatment of acute lymphoblastic leukemia in older adults: now and the future. Clinical Advances in Hematology and Oncology, 2017, 15, 266-274.	0.3	16
252	Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (<sc>AML</sc>) and myelodysplastic syndrome (<sc>MDS</sc>). American Journal of Hematology, 2016, 91, 227-232.	4.1	46

#	ARTICLE	IF	CITATIONS
253	Final results of a single institution experience with a pediatricâ€based regimen, the augmented Berlinâ€Frankfurtâ€MÃ¼nster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyperâ€CVAD regimen. American Journal of Hematology, 2016, 91, 819-823.	4.1	102
254	Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype. Blood, 2016, 127, 1863-1869.	1.4	253
255	Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. Blood, 2016, 127, 1269-1275.	1.4	119
256	Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosomeâ€negative acute lymphoblastic leukemia. Cancer, 2016, 122, 3812-3820.	4.1	17
257	Chronic myeloid leukemia: Firstâ€line drug of choice. American Journal of Hematology, 2016, 91, 59-66.	4.1	49
258	Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring. American Journal of Hematology, 2016, 91, 252-265.	4.1	139
259	Hyperâ€CVAD plus ponatinib versus hyperâ€CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosomeâ€positive acute lymphoblastic leukemia: A propensity score analysis. Cancer, 2016, 122, 3650-3656.	4.1	156
260	Impact of complete molecular response on survival in patients with Philadelphia chromosomeâ€positive acute lymphoblastic leukemia. Blood, 2016, 128, 504-507.	1.4	194
261	<i>TP53</i> mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes. Cancer, 2016, 122, 3484-3491.	4.1	200
262	Activity of the oral mitogenâ€activated protein kinase kinase inhibitor trametinib in <sc><i>RAS</i></sc>â€mutant relapsed or refractory myeloid malignancies. Cancer, 2016, 122, 1871-1879.	4.1	113
263	Minimal residual disease assessed by multiâ€parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. British Journal of Haematology, 2016, 172, 392-400.	2.5	102
264	Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 163-168.e2.	0.4	18
265	Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial. Lancet Oncology, The, 2016, 17, 496-508.	10.7	142
266	Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) As Frontline Therapy for Older Patients with Acute Lymphoblastic Leukemia (ALL): Interim Result of a Phase II Clinical Trial. Blood, 2016, 128, 588-588.	1.4	11
267	Phase IB/II Study of Nivolumab in Combination with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML). Blood, 2016, 128, 763-763.	1.4	53
268	Clinical implications of <i>TP53</i> mutations in myelodysplastic syndromes treated with hypomethylating agents. Oncotarget, 2016, 7, 14172-14187.	1.8	86
269	Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a <sc>CD</sc>22 monoclonal antibody. American Journal of Hematology, 2015, 90, 193-196.	4.1	35
270	Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib. Blood, 2015, 126, 790-797.	1.4	162



#	ARTICLE	IF	CITATIONS
271	New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia. <i>Cancer</i> , 2015, 121, 2517-2528.	4.1	200
272	Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Cancer</i> , 2015, 121, 4158-4164.	4.1	181
273	Monoclonal antibodies in acute lymphoblastic leukemia. <i>Blood</i> , 2015, 125, 4010-4016.	1.4	144
274	Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia. <i>Cancer</i> , 2015, 121, 556-561.	4.1	122
275	Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Haematologica</i> , 2015, 100, 653-661.	3.5	191
276	Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. <i>Lancet Haematology</i> , 2015, 2, e186-e193.	4.6	227
277	Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. <i>Lancet Oncology</i> , 2015, 16, 1025-1036.	10.7	129
278	Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials. <i>Lancet Haematology</i> , 2015, 2, e118-e128.	4.6	65
279	Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: Retrospective analysis of survival after long-term follow-up. <i>Leukemia Research</i> , 2015, 39, 520-524.	0.8	44
280	The role of ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 365-373.	2.4	21
281	Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. <i>Cancer</i> , 2015, 121, 2375-2382.	4.1	40
282	Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. <i>Lancet Oncology</i> , 2015, 16, 1547-1555.	10.7	245
283	Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study. <i>Lancet Haematology</i> , 2015, 2, e376-e383.	4.6	86
284	Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. <i>Lancet Oncology</i> , 2015, 16, 1099-1110.	10.7	249
285	Phase II Study of Cladribine, Idarubicin, and Cytarabine (araC) in Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2015, 126, 2541-2541.	1.4	7
286	Salvage Chemotherapy with Inotuzumab Ozogamicin (INO) Combined with Mini-Hyper-CVD for Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2015, 126, 3721-3721.	1.4	13
287	Frontline Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) for Older Patients with Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2015, 126, 83-83.	1.4	19
288	Phase II trial of HyperCVAD and Dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2014, 89, 282-287.	4.1	58

#	ARTICLE	IF	CITATIONS
289	Impact of comorbidities by ACEâ€²7 in the revisedâ€²PSS for patients with myelodysplastic syndromes. <i>American Journal of Hematology</i> , 2014, 89, 509-516.	4.1	30
290	Tyrosine Kinase Inhibitors as Initial Therapy for Patients With Chronic Myeloid Leukemia in Accelerated Phase. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 155-162.e1.	0.4	51
291	HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia. <i>Cancer</i> , 2014, 120, 373-380.	4.1	54
292	Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAGâ€²GO) as frontâ€²line regimen in patients with core binding factor acute myelogenous leukemia. <i>American Journal of Hematology</i> , 2014, 89, 964-968.	4.1	62
293	Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). <i>Blood</i> , 2014, 123, 494-500.	1.4	364
294	BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia. <i>Cancer Cell</i> , 2014, 26, 428-442.	16.8	292
295	Augmented Berlinâ€²Frankfurtâ€²Mâ€²1/4nster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). <i>Cancer</i> , 2014, 120, 3660-3668.	4.1	91
296	A Phase I Study of Fludarabine, Cytarabine, and Oxaliplatin Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 395-400.e1.	0.4	11
297	Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients â€²60 years with newly diagnosed acute myeloid leukemia. <i>American Journal of Hematology</i> , 2013, 88, 961-966.	4.1	46
298	Acquisition of cytogenetic abnormalities in patients with IPSS defined lowerâ€²risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia. <i>American Journal of Hematology</i> , 2013, 88, 831-837.	4.1	43
299	Similar Outcome of Patients With Chronic Myeloid Leukemia Treated With Imatinib in or Out of Clinical Trials. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 693-699.	0.4	6
300	Phase I Study Assessing the Safety and Tolerability of Barasertib (AZD1152) With Low-Dose Cytosine Arabinoside in Elderly Patients With AML. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 559-567.	0.4	48
301	Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. <i>Cancer</i> , 2013, 119, 2728-2736.	4.1	265
302	The Achievement of a 3-Month Complete Cytogenetic Response to Second-Generation Tyrosine Kinase Inhibitors Predicts Survival in Patients With Chronic Phase Chronic Myeloid Leukemia After Imatinib Failure. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 302-306.	0.4	20
303	Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: A retrospective case-control study. <i>American Journal of Hematology</i> , 2013, 88, 198-200.	4.1	13
304	Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus lowâ€²dose cytosine arabinoside in elderly patients with acute myeloid leukemia. <i>Cancer</i> , 2013, 119, 2611-2619.	4.1	88
305	Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities. <i>Blood</i> , 2013, 121, 4867-4874.	1.4	124
306	Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months. <i>Haematologica</i> , 2013, 98, 1686-1688.	3.5	29

#	ARTICLE	IF	CITATIONS
307	Phase II Trial of Vorinostat With Idarubicin and Cytarabine for Patients With Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome. <i>Journal of Clinical Oncology</i> , 2012, 30, 2204-2210.	1.6	158
308	Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. <i>Blood</i> , 2012, 119, 1981-1987.	1.4	298
309	Inotuzumab ozogamicin, an anti-CD22â€“calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. <i>Lancet Oncology</i> , The, 2012, 13, 403-411.	10.7	401
310	Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study. <i>Lancet Oncology</i> , The, 2012, 13, 1096-1104.	10.7	58
311	Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2012, 87, 687-691.	4.1	63
312	Final results of the phase II study of rabbit antiâ€“thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colonyâ€“stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome. <i>British Journal of Haematology</i> , 2012, 157, 312-320.	2.5	36
313	Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure. <i>Blood</i> , 2011, 117, 1822-1827.	1.4	64
314	Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations. <i>Blood</i> , 2011, 117, 3641-3647.	1.4	71
315	Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers. <i>Blood</i> , 2011, 118, 4690-4693.	1.4	88
316	The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. <i>Blood</i> , 2011, 118, 4541-4546.	1.4	133
317	Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia. <i>Blood</i> , 2011, 118, 6030-6036.	1.4	103
318	Front-Line Therapy With Second-Generation Tyrosine Kinase Inhibitors in Patients With Early Chronic Phase Chronic Myeloid Leukemia: What Is the Optimal Response?. <i>Journal of Clinical Oncology</i> , 2011, 29, 4260-4265.	1.6	71
319	A phase I study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and highâ€“risk myelodysplastic syndrome. <i>Cancer</i> , 2011, 117, 1236-1244.	4.1	36
320	Practical advice for determining the role of <i>BCR-ABL</i> mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. <i>Cancer</i> , 2011, 117, 1800-1811.	4.1	72
321	Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. <i>Blood</i> , 2010, 116, 4422-4429.	1.4	336
322	Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. <i>Cancer</i> , 2010, 116, 3830-3834.	4.1	241
323	Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration. <i>Cancer</i> , 2010, 116, 5568-5574.	4.1	104
324	Nilotinib As Front-Line Treatment for Patients With Chronic Myeloid Leukemia in Early Chronic Phase. <i>Journal of Clinical Oncology</i> , 2010, 28, 392-397.	1.6	231

#	ARTICLE	IF	CITATIONS
325	Results of Dasatinib Therapy in Patients With Early Chronic-Phase Chronic Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2010, 28, 398-404.	1.6	227
326	Significance of Increasing Levels of Minimal Residual Disease in Patients With Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia in Complete Cytogenetic Response. <i>Journal of Clinical Oncology</i> , 2009, 27, 3659-3663.	1.6	61
327	Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. <i>Cancer</i> , 2009, 115, 1899-1905.	4.1	191
328	Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. <i>Blood</i> , 2009, 113, 2154-2160.	1.4	151
329	Molecular monitoring in chronic myeloid leukemia. <i>Cancer</i> , 2008, 112, 2112-2118.	4.1	44
330	Evolution of decitabine development. <i>Cancer</i> , 2008, 112, 2341-2351.	4.1	187
331	Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. <i>Blood</i> , 2008, 112, 4839-4842.	1.4	75
332	Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. <i>Blood</i> , 2007, 109, 3214-3218.	1.4	174
333	Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. <i>Blood</i> , 2007, 110, 4005-4011.	1.4	284
334	Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. <i>Cancer</i> , 2007, 109, 265-273.	4.1	113
335	Current and emerging treatment options in chronic myeloid leukemia. <i>Cancer</i> , 2007, 109, 2171-2181.	4.1	115
336	Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma. <i>Cancer</i> , 2007, 109, 2481-2489.	4.1	138
337	Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia. <i>Cancer</i> , 2007, 110, 340-344.	4.1	66
338	Adult Acute Myeloid Leukemia. <i>Mayo Clinic Proceedings</i> , 2006, 81, 247-260.	3.0	103
339	Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. <i>Blood</i> , 2006, 108, 1421-1423.	1.4	85
340	Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome. <i>Cancer</i> , 2006, 106, 1090-1098.	4.1	550
341	Treatment of Graft Failure with Fludarabine (Flu), Antithymocyte Globulin (ATG) and a Second Allogeneic Stem Cell Transplantation (SCT). <i>Blood</i> , 2005, 106, 2734-2734.	1.4	0